Loading...
Please wait, while we are loading the content...
Similar Documents
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
| Content Provider | Semantic Scholar |
|---|---|
| Author | Uno, Miyuki Oba-Shinjo, Sueli Mieko Moura, Ricardo Pereira Aguiar, Paulo Henrique Pires De Cabrera, Hector Navarro Begnami, Marcos Rosemberg, Sérgio Teixeira, Manoel Jacobsen Marie, Suely Kazue Nagahashi |
| Copyright Year | 2011 |
| Abstract | OBJECTIVES 1) To correlate the methylation status of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter to its gene and protein expression levels in glioblastoma and 2) to determine the most reliable method for using MGMT to predict the response to adjuvant therapy in patients with glioblastoma. BACKGROUND The MGMT gene is epigenetically silenced by promoter hypermethylation in gliomas, and this modification has emerged as a relevant predictor of therapeutic response. METHODS Fifty-one cases of glioblastoma were analyzed for MGMT promoter methylation by methylation-specific PCR and pyrosequencing, gene expression by real time polymerase chain reaction, and protein expression by immunohistochemistry. RESULTS MGMT promoter methylation was found in 43.1% of glioblastoma by methylation-specific PCR and 38.8% by pyrosequencing. A low level of MGMT gene expression was correlated with positive MGMT promoter methylation (p = 0.001). However, no correlation was found between promoter methylation and MGMT protein expression (p = 0.297). The mean survival time of glioblastoma patients submitted to adjuvant therapy was significantly higher among patients with MGMT promoter methylation (log rank = 0.025 by methylation-specific PCR and 0.004 by pyrosequencing), and methylation was an independent predictive factor that was associated with improved prognosis by multivariate analysis. DISCUSSION AND CONCLUSION MGMT promoter methylation status was a more reliable predictor of susceptibility to adjuvant therapy and prognosis of glioblastoma than were MGMT protein or gene expression levels. Methylation-specific polymerase chain reaction and pyrosequencing methods were both sensitive methods for determining MGMT promoter methylation status using DNA extracted from frozen tissue. |
| Starting Page | 1747 |
| Ending Page | 1755 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| PubMed reference number | 22012047v1 |
| Volume Number | 66 |
| Journal | Clinics |
| Alternate Webpage(s) | http://www.producao.usp.br/bitstream/handle/BDPI/9887/art_UNO_Correlation_of_MGMT_promoter_methylation_status_with_2011.pdf;jsessionid=D463799DA8A12DECD7B9A719BDA5AEA3?sequence=1 |
| Alternate Webpage(s) | https://www.revistas.usp.br/clinics/article/download/19488/21551 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Extraction Forecast of outcome Gene Expression Glioblastoma Glioma Hypermethylation Methylation O(6)-Methylguanine-DNA Methyltransferase O-(6)-methylguanine Patients Pharmaceutical Adjuvants Pyrosequencing Real-Time Polymerase Chain Reaction adjuvant therapy predictive factor protein expression |
| Content Type | Text |
| Resource Type | Article |
